机构：[1]Department of Epileptology (Krankenhaus Mara),Medical School, Bielefeld University, Campus Bielefeld-Bethel[2]Society for Epilepsy Research ,Bielefeld, Germany[3]Department of Neurology,Odense University Hospital[4]Department of Clinical Research,University of Southern Denmark, Odense, Denmark[5]Department of Epileptology ,University Hospital Bonn, Germany[6]Department of Immunology and Biotechnology ,University of P´ecs, Medical School, Hungary[7]Department of Neurology,Erasmus Medical Center, Rotterdam, Zuid-Holland, the Netherlands[8]Division of Epilepsy,Department of Neurology, Mayo Clinic, Rochester, MN[9]NYU Comprehensive Epilepsy Center,New York[10]French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis ,Hospices Civils de Lyon, Hˆopital Neurologique, UMR MELIS Inserm 1314 / CNRS 5284, Universit´e Claude Bernard Lyon1, France[11]Department of Neurology,Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic[12]Department of Neurology,Columbia University Irving Medical Center (CUIMC)/New York Presbyterian Hospital, New York[13]Department of Neurology ,Medical School, University of P´ecs, P´ecs, Hungary[14]Division of Neurology,University of Toronto, Ontario, Canada[15]Epilepsy-Center Berlin-Brandenburg ,Department of Neurology, Charit´e - Universit¨atsmedizin Berlin, Germany[16]Department of Neurology,West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[17]Oxford Autoimmune Neurology Group,Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom[18]Department of Neurology and Neurosciences,Mayo Clinic, Jacksonville, FL[19]Department of Neurology with Institute of Translational Neurology,University Hospital M¨unster, Germany[20]Translational Neuroimmunology Group ,Kids Neuroscience Centre, Children’s Hospital at Westmead[21]Faculty of Medicine and Health, University of Sydney[22]Department of Neurology, Concord Hospital, Sydney, Australia[23]Division of Neurology,Department of Medicine, University of British Columbia, Vancouver, Canada[24]Laboratory Krone,Bad Salzuflen, Germany.
Patients with ongoing seizures are usually not allowed to drive. The prognosis for seizure freedom is favorable in patients with autoimmune encephalitis (AIE) with antibodies against NMDA receptor (NMDAR), leucine-rich glioma-inactivated 1 (LGI1), contactin-associated protein-like 2 (CASPR2), and the gamma-aminobutyric-acid B receptor (GABABR). We hypothesized that after a seizure-free period of 3 months, patients with AIE have a seizure recurrence risk of <20% during the subsequent 12 months. This would render them eligible for noncommercial driving according to driving regulations in several countries.This retrospective multicenter cohort study analyzed follow-up data from patients aged 15 years or older with seizures resulting from NMDAR-, LGI1-, CASPR2-, or GABABR-AIE, who had been seizure-free for ≥3 months. We used Kaplan-Meier (KM) estimates for the seizure recurrence risk at 12 months for each antibody group and tested for the effects of potential covariates with regression models.We included 383 patients with NMDAR-, 440 with LGI1-, 114 with CASPR2-, and 44 with GABABR-AIE from 14 international centers. After being seizure-free for 3 months after an initial seizure period, we calculated the probability of remaining seizure-free for another 12 months (KM estimate) as 0.89 (95% confidence interval [CI] 0.85-0.92) for NMDAR, 0.84 (CI 0.80-0.88) for LGI1, 0.82 (CI 0.75-0.90) for CASPR2, and 0.76 (CI 0.62-0.93) for GABABR.Taking a <20% recurrence risk within 12 months as sufficient, patients with NMDAR-AIE and LGI1-AIE could be considered eligible for noncommercial driving after having been seizure-free for 3 months.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|1 区医学
小类|1 区临床神经病学1 区神经科学
最新[2023]版：
大类|1 区医学
小类|1 区临床神经病学1 区神经科学
第一作者：
第一作者机构：[1]Department of Epileptology (Krankenhaus Mara),Medical School, Bielefeld University, Campus Bielefeld-Bethel
通讯作者：
推荐引用方式(GB/T 7714)：
Rada Anna,Hagemann Anne,Aaberg Poulsen Charlotte,et al.Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABABR Antibodies: Implications for Return to Driving[J].Neurology(R) Neuroimmunology & Neuroinflammation.2024,11(4):e200225.doi:10.1212/NXI.0000000000200225.
APA：
Rada Anna,Hagemann Anne,Aaberg Poulsen Charlotte,Baumgartner Tobias,Berki Timea...&Specht Ulrich.(2024).Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABABR Antibodies: Implications for Return to Driving.Neurology(R) Neuroimmunology & Neuroinflammation,11,(4)
MLA：
Rada Anna,et al."Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABABR Antibodies: Implications for Return to Driving".Neurology(R) Neuroimmunology & Neuroinflammation 11..4(2024):e200225
医学